Khiron Life Sciences Corp
Khiron Life Sciences Corp. operates as an integrated medical and cannabis company in Latin America and Europe. It operates through Health Services, Medical Cannabis Products, and Wellbeing Products segments. The company focuses on the cultivation, production, distribution, and export of tetrahydrocannabinol and cannabidiol (CBD) medical cannabis. It also operates a network of health centers and s… Read more
Khiron Life Sciences Corp (KHRNF) - Net Assets
Latest net assets as of September 2022: $27.10 Million USD
Based on the latest financial reports, Khiron Life Sciences Corp (KHRNF) has net assets worth $27.10 Million USD as of September 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($38.45 Million) and total liabilities ($11.35 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $27.10 Million |
| % of Total Assets | 70.49% |
| Annual Growth Rate | 61.04% |
| 5-Year Change | 24607.18% |
| 10-Year Change | 18557.39% |
| Growth Volatility | 6364.11 |
Khiron Life Sciences Corp - Net Assets Trend (2011–2021)
This chart illustrates how Khiron Life Sciences Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Khiron Life Sciences Corp (2011–2021)
The table below shows the annual net assets of Khiron Life Sciences Corp from 2011 to 2021.
| Year | Net Assets | Change |
|---|---|---|
| 2021-12-31 | $33.33 Million | -47.29% |
| 2020-12-31 | $63.23 Million | -9.72% |
| 2019-12-31 | $70.04 Million | +174.26% |
| 2018-12-31 | $25.54 Million | +18831.18% |
| 2017-12-31 | $134.90K | +225.00% |
| 2016-12-31 | $-107.91K | -11.41% |
| 2015-12-31 | $-96.86K | -2048.93% |
| 2014-12-31 | $4.97K | -82.04% |
| 2013-12-31 | $27.68K | -84.51% |
| 2012-12-31 | $178.64K | -37.09% |
| 2011-12-31 | $283.93K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Khiron Life Sciences Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11664752100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2021)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $146.45 Million | 439.40% |
| Other Comprehensive Income | $3.69 Million | 11.08% |
| Total Equity | $33.33 Million | 100.00% |
Khiron Life Sciences Corp Competitors by Market Cap
The table below lists competitors of Khiron Life Sciences Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Notoria
WAR:NTS
|
$20.54K |
|
EUTELSAT COMM.
MU:E3B
|
$20.56K |
|
Fonix Mobile plc
LSE:FNX
|
$20.56K |
|
Liontrust Asset Management
LSE:LIO
|
$20.57K |
|
Eckoh Plc
LSE:ECK
|
$20.49K |
|
Pressure Biosciences Inc
OTCQB:PBIO
|
$20.48K |
|
BHB BRAUHOLDING
MU:B9B
|
$20.48K |
|
Gamer Pakistan Inc. Common Stock
PINK:GPAK
|
$20.46K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Khiron Life Sciences Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2020 to 2021, total equity changed from 63,228,987 to 33,329,000, a change of -29,899,987 (-47.3%).
- Net loss of 33,129,000 reduced equity.
- New share issuances of 11,002,000 increased equity.
- Other comprehensive income decreased equity by 6,139,118.
- Other factors decreased equity by 1,633,869.
Equity Change Factors (2020 to 2021)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-33.13 Million | -99.4% |
| Share Issuances | $11.00 Million | +33.01% |
| Other Comprehensive Income | $-6.14 Million | -18.42% |
| Other Changes | $-1.63 Million | -4.9% |
| Total Change | $- | -47.29% |
Book Value vs Market Value Analysis
This analysis compares Khiron Life Sciences Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $2.54 | $0.00 | x |
| 2012-12-31 | $1.27 | $0.00 | x |
| 2013-12-31 | $0.11 | $0.00 | x |
| 2014-12-31 | $0.02 | $0.00 | x |
| 2015-12-31 | $-0.51 | $0.00 | x |
| 2016-12-31 | $-0.57 | $0.00 | x |
| 2017-12-31 | $0.00 | $0.00 | x |
| 2018-12-31 | $0.53 | $0.00 | x |
| 2019-12-31 | $0.69 | $0.00 | x |
| 2020-12-31 | $0.53 | $0.00 | x |
| 2021-12-31 | $0.20 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Khiron Life Sciences Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -99.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -258.92%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.27x
- Recent ROE (-99.40%) is above the historical average (-593.77%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -2.79% | 0.00% | 0.00x | 1.09x | $-36.31K |
| 2012 | -116.36% | 0.00% | 0.00x | 1.19x | $-225.73K |
| 2013 | -453.43% | 0.00% | 0.00x | 4.27x | $-128.27K |
| 2014 | -2329.90% | 0.00% | 0.00x | 7.06x | $-116.29K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-49.87K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-33.89K |
| 2017 | -3362.07% | 0.00% | 0.00x | 1.09x | $-4.55 Million |
| 2018 | -77.56% | -2221.27% | 0.02x | 1.58x | $-22.36 Million |
| 2019 | -51.94% | -379.63% | 0.12x | 1.17x | $-43.38 Million |
| 2020 | -38.02% | -299.85% | 0.11x | 1.16x | $-30.36 Million |
| 2021 | -99.40% | -258.92% | 0.30x | 1.27x | $-36.46 Million |
Industry Comparison
This section compares Khiron Life Sciences Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Khiron Life Sciences Corp (KHRNF) | $27.10 Million | -2.79% | 0.42x | $20.49K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |